Drug Profile
Aflibercept biosimilar - Coherus BioSciences
Alternative Names: CHS-2020Latest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Coherus BioSciences
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders